



For Immediate Release

H&T Corporation
2-20-4 Morikawachi-nishi, Higashi-Osaka City, Osaka 577-0061 JAPAN
TEL: 81-6-6785-3322 / FAX: 81-6-6785-3435
Email: mail@ht21.co.jp Website: <http://www.ht21.co.jp/>

H & T Receives Combined Investment of 100.5 Million Yen from ORIX Fund No. 11 and the Mie New Industry & Innovation Fund No. 2

(November 26, 2007 - Osaka, Japan) – On October 12, 2007, the H & T Corporation received investments of 60 Million Yen from the ORIX Capital Corporation (managing party of ORIX Fund No. 11) and 40.5 Million Yen from Future Venture Capital Co. Ltd. (managing party of the Mie New Industry & Innovation Fund No. 2), with both investments made through third party stock allocation increases. As a result of these investments, H&T's capital has grown from 90.7 million yen to 145 million yen. This investment fund will be directed toward the further development of H&T's pharmaceutical safety trial support system.

The H&T Corporation was founded in 1998, and is currently working on the development of its "TOX-LAUNCHER" pharmaceutical safety trial support system. The system, which is sold as packaged software, gathers and compiles data from the preclinical animal testing stage in the development of new pharmaceutical products. The system is compliant with both Good Laboratory Practice (GLP) and FDA21 CFR Part11 regulations, and can be used to realize reductions in the cost and labor involved with administering preclinical trials. With novel features such as the system's selectable installation format, which allows the user to choose from various menus only those system components that are necessary for his or her particular study, and the system's 'Auto-Validation' function, which automatically performs Operational Qualification (OQ) for the system, the user is given flexibility in both system installation and operation.

The system is three fifths complete, with Japanese language versions of the Pathology Subsystem, Weight Measurement Subsystem, and Clinical Pathology Subsystem all available for purchase, and has already received high praise from pharmaceutical companies that have had the system installed. With the increase in capital mentioned above, the company is aiming to accelerate the development of the two remaining subsystems (the Clinical Observation Subsystem and the Reproductive Toxicity Test Subsystem) and complete the entire system ahead of schedule.